share_log

Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target

Benzinga ·  Sep 24 20:00  · Ratings

Benchmark analyst Bruce Jackson reiterates NeoGenomics (NASDAQ:NEO) with a Buy and maintains $18 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment